CompletedPhase IInterventional

Phase 1 Trial: Quotient Code QSC303303, Sponsor Code LMNL6511C1002

This is a Phase 1 clinical trial, which means it's one of the first times this new treatment, known as QSC303303, is being tested in humans. The main purpose of these early studies is to see how safe the treatment is and how the body handles it. This trial includes people aged 18 to 65. For now, specific details about what conditions it aims to treat and the exact intervention methods are not publicly available. The organisers of the trial will release a full report with all the details within 30 months after the study has officially ended. This is a common practice to allow researchers to gather and analyse all the information properly.

At a glance

Status

Completed

Phase

Phase I

Sponsor

Liminal BioSciences Limited

Enrolment target

Start

02 Jun 2025

Estimated completion

04 May 2026

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

This study is a 'Phase 1' clinical trial. Think of it as the very first step in testing a new medicine or treatment in people. The main goal at this stage isn't to see if the treatment works for a specific illness, but rather to make sure it's safe and to understand how the body reacts to it. Researchers will carefully check for any side effects and work out the right dose.

The specific treatment being looked at in this trial is identified by a code: QSC303303. We don't have all the details about what this treatment is for or how it's given right now. This is because the trial organisers have decided to release the full information a bit later. This isn't unusual and allows them to gather and study all the data thoroughly before sharing it widely.

While we can't tell you exactly what this treatment targets, participating in a Phase 1 trial contributes valuable information to medical science. It helps bring potential new treatments closer to people who might need them in the future. The full results of this study will be made public within 30 months after the trial has been completed, giving us a clearer picture of its findings.

Key takeaways

This is an early-stage (Phase 1) study for a new treatment called QSC303303.
The main focus of this study is to check the safety of the treatment.
Participants must be between 18 and 65 years old.
More detailed information about the study will be released within 30 months after it ends.
Taking part helps advance medical research for potential future treatments.

Who may be eligible?

To be considered for this study, you would need to be an adult, specifically between 18 and 65 years old. Both men and women are welcome to take part in this research.

At this point, the specific health conditions, or lack thereof, that would make someone suitable for the study are not yet publicly known. This also applies to any health issues that might prevent someone from joining.

Once the full details of the study are released, we will have a much clearer idea of the exact health criteria that participants need to meet.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you between 18 and 65 years old?
Are you a man or a woman?
Are you able to commit to several clinic visits?
Are you comfortable with receiving a new, untested treatment?
Do you understand that the main goal is safety, not treating an illness?

Answer every question to see your result.

What does participation involve?

As this is a Phase 1 study, participation usually involves several visits to a clinic or research centre. These visits might include health checks, blood tests, and other assessments to monitor your health and how your body reacts to the study treatment. You would be given the new treatment, QSC303303, and doctors and nurses would keep a close eye on you.

The total duration of your involvement could vary, but Phase 1 trials often involve a period of treatment followed by a follow-up period to ensure your well-being. The exact schedule, including how many visits, the types of assessments, and the length of your participation, will only be available once the full study details are released. It's important to know that you'd be guided through every step by the study team.

Potential risks and benefits

Taking part in an early-stage study like this means you are helping to advance medical knowledge, which is a significant potential benefit. However, because it's a new treatment, there is always a chance of unknown side effects. We don't yet have specific details on the potential benefits for participants or the direct risks involved, as this information will be shared later. It is very important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Quotient Sciences Limited
City only
Nottingham, United Kingdom

Common questions

What is a Phase 1 trial?

A Phase 1 trial is the first step where a new treatment is tested in people. The main aim is to check its safety and how the body handles it, rather than if it treats a specific illness.

What is the treatment called?

The new treatment being studied is identified by the code QSC303303.

Who can take part?

Adults between 18 and 65 years old, both men and women, are eligible to be considered for this study.

When will more details be available?

Full details about the trial will be made public within 30 months after the study has officially ended.

Will I get better if I join this trial?

The primary goal of a Phase 1 trial is to check safety, not to treat a specific condition. Any potential benefits would be clearer in later stages of research.

How to find out more

Clinical Trial Information

info@liminalbiosciences.com - Official trial record

Always speak to your GP or specialist before deciding to take part in a study.